S&P 500 · Pharma · GLP-1 supercycle leader
Lilly (Eli)
Eli Lilly dominates the obesity/diabetes supercycle with its GIP/GLP-1 dual agonist tirzepatide (Mounjaro, Zepbound) (NYSE LLY, S&P 500). FY2025 growth — revenue $65.2bn (+45%), net income $20.6bn (+95%) — is effectively all tirzepatide: Mounjaro plus Zepbound totaled $36.5bn, 56% of company revenue, overtaking Merck's Keytruda ($31.6bn) as the world's #1 drug franchise, with obesity drug Zepbound up +175%. The franchise's bottleneck is supply, not demand — demand is near-unlimited and the real revenue ceiling is set by manufacturing capacity (2025 capacity up 1.6x, new U.S. sites) and insurance coverage. The next re-rating trigger is oral GLP-1 orforglipron (2026 launch), which relaxes injectable limits and re-expands the addressable market.
LLY Updated Jul 12, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Lilly (Eli) is directly linked to 4 companies (1 supply, 3 revenue relationships) and reaches 5 companies within two hops; the links are backed by 7 dated sources, 2 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · $65.18bn (FY2025, +45%)
- Customer concentration · The year 56% of revenue concentrated in one franchise, tirzepatide — the bottleneck is capacity and insurance coverage, not demand. Net income $20.6bn (+95%), 67% U.S. ($43.5bn). Next legs: oral orforglipron (2026) and Alzheimer's donanemab. FY2026 guidance $80-83bn.
- Segments · Incretins (tirzepatide: Mounjaro, Zepbound) · Legacy diabetes & other · Oncology, immunology & neuroscience (Verzenio, donanemab)
Revenue from
- Obesity & diabetes prescription demand (tirzepatide) High confidence· Amount $36.5B · FY2025 티르제파티드
The entirety of growth and now the world's #1 drug franchise — tirzepatide (Mounjaro $23.0B, +99%; Zepbound $13.5B, +175%) totaled $36.5B, 56% of FY2025 revenue, overtaking Merck's Keytruda ($31.6B). The bottleneck is supply, not demand: demand is effectively unlimited, and the real revenue ceiling is set by manufacturing capacity and insurance coverage. The next leg is oral orforglipron (2026 launch), which relaxes injectable constraints and re-expands the market.Mentions EN Morgan Stanley (via TipRanks) Published Jul 8, 2026: Morgan Stanley raises Eli Lilly target to $1,347, keeps OverweightConfirms KO Financial News (KR) Published Nov 22, 2025: Zepbound maker Eli Lilly crosses $1 trillion market capConfirms EN European Pharmaceutical Review Published May 1, 2025: Lilly boosts Lebanon site to $9B for tirzepatide APIConfirms EN Fierce Pharma Published Apr 1, 2025: Lilly commits $3B to China manufacturing, local CDMO partnerships - Cardinal Health (US wholesaler, big three) High confidence· Market share 10% · FY2025 (각 10%+)
A direct channel for Lilly's revenue — the 10-K discloses that the three U.S. wholesalers (McKesson, Cencora, Cardinal) each account for 10%+ of consolidated revenue. Lilly sells to these wholesalers rather than pharmacies, so as one of the big three, this distribution concentration is both channel bargaining power and the layer where the gross-to-net gap (rebates, PBMs) forms. - McKesson (US wholesaler, big three) High confidence· Market share 10% · FY2025 (각 10%+)
A direct channel for Lilly's revenue — the 10-K discloses that the three U.S. wholesalers (McKesson, Cencora, Cardinal) each account for 10%+ of consolidated revenue. Lilly sells to these wholesalers rather than pharmacies, so as the largest U.S. wholesaler, this distribution concentration is both channel bargaining power and the layer where the gross-to-net gap (rebates, PBMs) forms. - Cencora (US wholesaler, big three) High confidence· Market share 10% · FY2025 (각 10%+)
A direct channel for Lilly's revenue — the 10-K discloses that the three U.S. wholesalers (McKesson, Cencora, Cardinal) each account for 10%+ of consolidated revenue. Lilly sells to these wholesalers rather than pharmacies, so (formerly AmerisourceBergen), this distribution concentration is both channel bargaining power and the layer where the gross-to-net gap (rebates, PBMs) forms.
Pays to
- ABL Bio High confidence· Amount 3,807,246,400,000원 · ABL 그랩바디-B 라이선스인 · Total KRW 3,807.2bn, upfront KRW 58.5bn
A pipeline bet beyond incretins — Lilly licensed ABL Bio's Grabody-B blood-brain-barrier (BBB) shuttle platform for up to KRW 3,807.2bn (~$2.6B), with a KRW 58.5bn ($40M) upfront, to develop and commercialize multiple targets. It is a long-dated option to diversify an obesity-heavy revenue base into neuroscience and beyond. - CDMO·충전 파트너 (비공개) Medium confidence
An external buffer on the capacity ramp — the GLP-1 injectable bottleneck lies more in sterile fill-finish than in API, so Lilly uses external CDMO and fill-finish partners alongside its own buildout. Individual contracts are mostly undisclosed, but this outsourcing headroom is the lever that raises the near-term capacity ceiling.Mentions EN Fierce Pharma Published Apr 1, 2025: Lilly commits $3B to China manufacturing, local CDMO partnerships
Investments
- Manufacturing capacity buildout (Lebanon API, China, new US sites) High confidence· Amount $9B · 레바논 API 사이트
Upfront investment where capacity is the revenue ceiling — the Lebanon, Indiana tirzepatide API site was raised from $3.7B to $9B (online end-2026), plus $3B in China and multiple new U.S. sites. Lilly lifted 2025 production capacity to 1.6x the prior year, and this capacity ramp effectively pre-commits future revenue. Separate lines are being built for oral orforglipron.Confirms EN European Pharmaceutical Review Published May 1, 2025: Lilly boosts Lebanon site to $9B for tirzepatide APIConfirms EN Fierce Pharma Published Apr 1, 2025: Lilly commits $3B to China manufacturing, local CDMO partnerships
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Cardinal Health | lead1 | -0.4 | +54.1 | +34.1 | +19 | +76.3 | +15.6 |
| McKesson Corporation | lead1 | +44.2 | +51.8 | +24.1 | +23.7 | +44.5 | -1.6 |
| Cencora | lead1 | +44.1 | +26.3 | +25.3 | +10.4 | +51.5 | -9.8 |
| Lilly (Eli) | node | +66.1 | +34.3 | +60.9 | +33.3 | +40.2 | +11 |
| ABL Bio | benef1 | +15.9 | -31.3 | +14.2 | +65.2 | +443.9 | -58.6 |
| Bristol Myers Squibb | benef2 | +2.9 | +19 | -26.1 | +15.8 | +0.1 | +10.4 |
YTD as of 2026-07-10 · source: Yahoo Finance
Eli Lilly's thesis is a franchise that dominates the obesity/diabetes supercycle with the GIP/GLP-1 dual agonist tirzepatide. FY2025 revenue of $65.2bn (+45%) and net income of $20.6bn (+95%) are essentially all tirzepatide — Mounjaro plus Zepbound at a combined $36.5bn is 56% of company revenue, overtaking Merck's Keytruda ($31.6bn) to become the world's top drug, with obesity drug Zepbound up +175%. The bottleneck here is supply, not demand — demand is effectively unlimited and the real revenue ceiling is set by manufacturing capacity (the Lebanon API site raised to $9bn, new US sites) and insurance coverage. But 56% of revenue concentrated in one franchise and 67% US exposure are structural risks. The next re-rating triggers are oral GLP-1 orforglipron (2026), which removes the injection constraint, and Alzheimer's donanemab — expanding the market itself.
Analysis generated from returns as of 2026-07-10